Skip to NavigationSkip to content


Top Ten most popular articles on this week

As me move startlingly quickly towards Easter, it's time for another Top Ten rundown.

This week, Celgene surprised the industry by goign against the grain to invest in neuroscience, sealing a potential $2.2 billion drug development deal. The news that a male contraceptive pill currently in development also made waves by proving its safety in clinical studies. But the week's most popular story, perhaps unsurprisingly, was the news that Novartis is set to step into the medical marijuana market, partnering with a producer of the products in Canada.

Independent committee report seeks Brexit healthcare clarity

An independent report, entitled Brexit – Medicines, Medical Devices and Substances of Human Origin and written by the Health and Social Care Committee, has called for greater clarity regarding the future for medicine access post-Brexit.

The committee puts forward that this should be one of the major issues in negotiations, given that the health of the entire UK populations rests on the outcome of talks on this area.

Pharmafocus March 2018 is available to read online now!

Though never truly out of vogue, the drug pricing debate has flared up again with the White House’s release of the white paper Reforming Biopharmaceutical Pricing at Home and Abroad. The report asserts that the United States’ healthcare bill – the largest in the world per capita by quite a margin – is due to inefficient regulation and foreign governments which demand universal healthcare and low prices for their citizens, leaving the US to foot the rest of the bill and allow manufacturers to see a return on their investments.

Top Ten most popular articles on this week

It's the first Friday of February, and it's time for another recap of the top ten articles most popular with our readers this week.

Read Pharmafocus January/February 2018 edition online now!

With the holiday period a distant memory by now, Pharmafocus is back with its January/febraury edition. It’s hard to imagine a more explosive start to the year, as the dust that had settled on a year characterised by stagnation in the mergers & acquisitions department is swiftly blown away with two major deals in one day: Sanofi shells out $11.6 billion for Bioverativ, and Celgene splashes $9 billion to acquire the rest of Juno Therapeutics.

Delivering the life sciences agenda: Easy as ABC

Published on 29/01/18 at 11:27am
IMAGE: Cambridge Biomedical Campus

Andrew Blevins and Andrew Carrington of Liberty Property Trust and Countryside Properties explain how organisations at the Cambridge Biomedical Campus are working to deliver the government’s life sciences agenda, and how other clusters across the UK can learn from their approach

Brexit Health Alliance warns of UK at back of the medicine queue

The Brexit Health Alliance (BHA) has cautioned that unless a favourable deal is struck, the UK could end Brexit negotiations as a comparatively small patient population in a global market – putting the country to the back of the queue in bringing new medicines to its shores.

The measurement underpinning government goals for UK life sciences

Published on 22/01/18 at 11:51am
Image Credit: Nicolas Raymond,

Michael Adeogun, Head of Life Sciences and Health at National Physical Laboratory, discusses the importance of effective measurement for the life sciences industry in achieving the key goals outlined in Sir John Bell’s Life Sciences Industrial Strategy, the UK Government’s accompanying Sector Deal and beyond.'s top ten stories of 2017

After a packed year that has flown by, we've reached the final top ten of 2017. Below you can find the biggest stories of the year that proved most popular with our readers.

It's been a year characterised by uncertainty and scandal, but eventful throughout. From J&J's massive acquisition of Actelion bringing in the year, to Teva's increasingly tragic fall from grace and the shadows cast on the industry and beyond by President Trump and Brexit, 2017 was a standout year for more than just a few reasons.

EMA Headquarters: There’s no place like home

Published on 13/11/17 at 11:07am

With the result of the Brexit referendum, the future of the EMA’s London headquarters was cast in doubt. Now, 19 EU member states are bidding to become the new home of the agency. It's now only one week away from the decision as to which city will host the agency and the competition is fierce.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches